Activating Compound | Comment | Organism | Structure |
---|---|---|---|
anti-Ro/SSA autoantibody | i.e. antinuclear autoantibodies in the blood directed against Ro/Sjögren's syndrome ribonucleoprotein A antigen. Adalimumab appears to be significantly more efficacious than Etanercept in preventing TACE activation caused by anti-Ro/SSA autoantibodies | Homo sapiens |
Application | Comment | Organism |
---|---|---|
medicine | anti-Ro/SSA autoantibodies determine TACE pro-domain shedding suggesting that TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA autoantibody-stimulated cells. Adalimumab appears to be significantly more efficacious than Etanercept in preventing TACE activation caused by anti-Ro/SSA autoantibodies. Regulation of TACE may participate in the pathogenic role of autoantibodies and the modulation of TACE expression by TNF-alpha antagonists might contribute to the beneficial effect of these drugs in inflammatory and autoimmune diseases | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
epithelial cell | salivary gland epithelial cell | Homo sapiens | - |
General Information | Comment | Organism |
---|---|---|
physiological function | anti-Ro/SSA autoantibodies determine TACE pro-domain shedding suggesting that TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA autoantibody-stimulated cells. Adalimumab appears to be significantly more efficacious than Etanercept in preventing TACE activation caused by anti-Ro/SSA autoantibodies. Regulation of TACE may participate in the pathogenic role of autoantibodies and the modulation of TACE expression by TNF-alpha antagonists might contribute to the beneficial effect of these drugs in inflammatory and autoimmune diseases | Homo sapiens |